Narcotrend Versus Bispectral Index Monitoring During Sufentanil-Midazolam Anesthesia for Bronchoscopy
Status:
Completed
Trial end date:
2019-01-30
Target enrollment:
Participant gender:
Summary
This study was aimed to determine whether narcotrend monitoring was better than bispectral
index monitoring during sufentanil-midazolam anesthesia for bronchoscopy under conscious
sedation. Patients were randomised to receive Narcotrend, Bispectral Index(BIS) monitoring or
without monitoring. Midazolam was given by non-anaesthetist physicians to achieve moderate
levels of sedation as assessed by the narcotrend index (NI; B and C) or bispectral index
(BIS; between 70 and 85) or according to patient's tolerance assessed by physician . The
primary end-point was dosage of midazolam. Other end-points included adverse events, patient
tolerance and physician satisfaction.